Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-11-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpatientradiationevidence ofcell
  Phrases that lowered it: evaluatepatients whoand safetyvaccinebleeding
• Phase: 3 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 28.7% (raises risk) · Drug's FDA history
• Sponsor's past termination rate: 10.0% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 250 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 219 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 98.5% (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Design: not given (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 NCT01566747 · started 2011 · scored riskier than 35% of active trials completed
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma NCT00720941 · started 2008 · scored riskier than 53% of active trials completed
• Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma NCT01513187 · started 2011 · scored riskier than 59% of active trials completed
• Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma NCT00731211 · started 2008 · scored riskier than 65% of active trials completed
• Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) NCT01613846 · started 2012 · scored riskier than 43% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.